Combination attenuation offers strategy for live attenuated coronavirus vaccines

Journal of Virology

Volumn 92, Issue 17, 2018, Pages

  Menachery, Vineet D ^a,b   Gralinski, Lisa E ^b   Mitchell, Hugh D ^d   Dinnon, Kenneth H ^b   Leist, Sarah R ^b   Yount, Boyd L ^b   McAnarney, Eileen T ^a,b   Graham, Rachel L ^b   Waters, Katrina M ^d   Baric, Ralph S ^b,c  

^a University of Texas Medical Branch School of Medicine   (United States)

^b IL   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

Author keywords

Aged; Coronavirus; Live attenuated; MERS CoV; SARS CoV; Vaccine

Indexed keywords

2' O METHYLTRANSFERASE; EXONUCLEASE; LIVE VACCINE; METHYLTRANSFERASE; PROTEIN METHYLTRANSFERASE; UNCLASSIFIED DRUG; ARCHAEAL PROTEIN; METHYLCOBALAMIN-COENZYME M METHYLTRANSFERASE; NSP16 PROTEIN, SARS VIRUS; VIRAL PROTEIN; VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORONAVIRUS INFECTION; ENZYME ACTIVITY; MOUSE; NONHUMAN; OPEN READING FRAME; PATHOGENESIS; PREVENTIVE MEDICINE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROTEIN MOTIF; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; SEVERE ACUTE RESPIRATORY SYNDROME; VERO CELL LINE; VIRUS LOAD; VIRUS REPLICATION; VIRUS TITRATION; VIRUS VIABILITY; AGING; ANIMAL; BAGG ALBINO MOUSE; CHLOROCEBUS AETHIOPS; CORONAVIRINAE; DISEASE MODEL; GENETICS; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; METHYLATION; MUTATION; SARS CORONAVIRUS; VIROLOGY;

AGING; ANIMALS; ARCHAEAL PROTEINS; CERCOPITHECUS AETHIOPS; CORONAVIRUS; CORONAVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; IMMUNOCOMPROMISED HOST; METHYLATION; METHYLTRANSFERASES; MICE; MICE, INBRED BALB C; MUTATION; SARS VIRUS; VACCINES, ATTENUATED; VERO CELLS; VIRAL NONSTRUCTURAL PROTEINS; VIRAL VACCINES; VIRUS REPLICATION;

EID: 85051814705     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00710-18     Document Type: Article

References (39)

1. Perlman S, Netland J. 2009. Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol 7:439-450. https://doi.org/ 10.1038/nrmicro2147
2. Cunningham AA, Daszak P, Wood JLN. 2017. One Health, emerging infectious diseases and wildlife: two decades of progress? Philos Trans R Soc Lond B Biol Sci 372:20160167. https://doi.org/10.1098/rstb.2016.0167
3. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. 2012. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367:1814-1820. https://doi.org/10.1056/ NEJMoa1211721
4. Menachery VD, Graham RL, Baric RS. 2017. Jumping species-a mechanism for coronavirus persistence and survival. Curr Opin Virol 23:1-7. https://doi.org/10.1016/j.coviro.2017.01.002
5. Fehr AR, Channappanavar R, Perlman S. 2017. Middle East respiratory syndrome: emergence of a pathogenic human coronavirus. Annu Rev Med 68:387-399. https://doi.org/10.1146/annurev-med-051215-031152
6. Stockman LJ, Bellamy R, Garner P. 2006. SARS: systematic review of treatment effects. PLoS Med 3:e343. https://doi.org/10.1371/journal.pmed.0030343
7. Menachery VD, Yount BL, Jr, Debbink K, Agnihothram S, Gralinski LE, Plante JA, Graham RL, Scobey T, Ge XY, Donaldson EF, Randell SH, Lanzavecchia A, Marasco WA, Shi ZL, Baric RS. 2015. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat Med 21:1508-1513. https://doi.org/10.1038/nm.3985
8. Kilianski A, Baker SC. 2014. Cell-based antiviral screening against coronaviruses: developing virus-specific and broad-spectrum inhibitors. Antiviral Res 101:105-112. https://doi.org/10.1016/j.antiviral.2013.11.004
9. Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, Leist SR, Pyrc K, Feng JY, Trantcheva I, Bannister R, Park Y, Babusis D, Clarke MO, Mackman RL, Spahn JE, Palmiotti CA, Siegel D, Ray AS, Cihlar T, Jordan R, Denison MR, Baric RS. 2017. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 9:eaal3653. https://doi.org/10.1126/scitranslmed.aal3653
10. Graham RL, Donaldson EF, Baric RS. 2013. A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Microbiol 11:836-848. https://doi.org/10.1038/nrmicro3143
11. Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. 2016. Coronaviruses: drug discovery and therapeutic options. Nat Rev Drug Discov 15:327-347. https://doi.org/10.1038/nrd.2015.37
12. Menachery VD, Mitchell HD, Cockrell AS, Gralinski LE, Yount BL, Jr, Graham RL, McAnarney ET, Douglas MG, Scobey T, Beall A, Dinnon K, III, Kocher JF, Hale AE, Stratton KG, Waters KM, Baric RS. 2017. MERS-CoV accessory ORFs play key role for infection and pathogenesis. mBio 8:e00665-17. https://doi.org/10.1128/mBio.00665-17
13. Chafekar A, Fielding BC. 2018. MERS-CoV: understanding the latest human coronavirus threat. Viruses 10:E93. https://doi.org/10.3390/v10020093
14. Bolles M, Deming D, Long K, Agnihothram S, Whitmore A, Ferris M, Funkhouser W, Gralinski L, Totura A, Heise M, Baric RS. 2011. A doubleinactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J Virol 85: 12201-12215. https://doi.org/10.1128/JVI.06048-11
15. Deming D, Sheahan T, Heise M, Yount B, Davis N, Sims A, Suthar M, Harkema J, Whitmore A, Pickles R, West A, Donaldson E, Curtis K, Johnston R, Baric R. 2006. Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med 3:e525. https://doi.org/10.1371/journal.pmed.0030525
16. Graham RL, Becker MM, Eckerle LD, Bolles M, Denison MR, Baric RS. 2012. A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease. Nat Med 18:1820-1826. https://doi.org/10.1038/nm.2972
17. Jimenez-Guardeno JM, Regla-Nava JA, Nieto-Torres JL, DeDiego ML, Castano-Rodriguez C, Fernandez-Delgado R, Perlman S, Enjuanes L. 2015. Identification of the mechanisms causing reversion to virulence in an attenuated SARS-CoV for the design of a genetically stable vaccine PLoS Pathog 11:e1005215. https://doi.org/10.1371/journal.ppat.1005215
18. Zust R, Cervantes-Barragan L, Habjan M, Maier R, Neuman BW, Ziebuhr J, Szretter KJ, Baker SC, Barchet W, Diamond MS, Siddell SG, Ludewig B, Thiel V. 2011. Ribose 2=-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5. Nat Immunol 12:137-143. https://doi.org/10.1038/nrm3071
19. Menachery VD, Yount BL, Jr, Josset L, Gralinski LE, Scobey T, Agnihothram S, Katze MG, Baric RS. 2014. Attenuation and restoration of severe acute respiratory syndrome coronavirus mutant lacking 2=-Omethyltransferase activity. J Virol 88:4251-4264. https://doi.org/10.1128/JVI.03571-13
20. Menachery VD, Gralinski LE, Mitchell HD, Dinnon KH, III, Leist SR, Yount BL, Jr, Graham RL, McAnarney ET, Stratton KG, Cockrell AS, Debbink K, Sims AC, Waters KM, Baric RS. 2017. Middle East respiratory syndrome coronavirus nonstructural protein 16 is necessary for interferon resistance and viral pathogenesis. mSphere 2:e00346-17. https://doi.org/10.1128/mSphere.00346-17
21. Menachery VD, Gralinski L, Mitchell HD, Dennon K, III, Leist SR, Yount B, McAnarney ET, Graham RL, Waters KM, Baric RS. 2018. Combination attenuation offers strategy for live attenuated coronavirus vaccines. bioRxiv https://doi.org/10.1101/309591
22. DeDiego ML, Nieto-Torres JL, Jimenez-Guardeno JM, Regla-Nava JA, Castano-Rodriguez C, Fernandez-Delgado R, Usera F, Enjuanes L. 2014. Coronavirus virulence genes with main focus on SARS-CoV envelope gene. Virus Res 194:124-137. https://doi.org/10.1016/j.virusres.2014.07.024
23. Menachery VD, Debbink K, Baric RS. 2014. Coronavirus nonstructural protein 16: evasion, attenuation, and possible treatments. Virus Res 194:191-199. https://doi.org/10.1016/j.virusres.2014.09.009
24. Netland J, DeDiego ML, Zhao J, Fett C, Alvarez E, Nieto-Torres JL, Enjuanes L, Perlman S. 2010. Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease. Virology 399:120-128. https://doi.org/ 10.1016/j.virol.2010.01.004
25. Almazan F, DeDiego ML, Sola I, Zuniga S, Nieto-Torres JL, Marquez-Jurado S, Andres G, Enjuanes L. 2013. Engineering a replicationcompetent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate. mBio 4:e00650-13. https://doi.org/ 10.1128/mBio.00650-13
26. Fett C, DeDiego ML, Regla-Nava JA, Enjuanes L, Perlman S. 2013. Complete protection against severe acute respiratory syndrome coronavirusmediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein. J Virol 87:6551-6559. https:// doi.org/10.1128/JVI.00087-13
27. Regla-Nava JA, Nieto-Torres JL, Jimenez-Guardeno JM, Fernandez-Delgado R, Fett C, Castano-Rodriguez C, Perlman S, Enjuanes L, DeDiego ML. 2015. Severe acute respiratory syndrome coronaviruses with mutations in the E protein are attenuated and promising vaccine candidates. J Virol 89:3870-3887. https://doi.org/10.1128/JVI.03566-14
28. Roberts A, Paddock C, Vogel L, Butler E, Zaki S, Subbarao K. 2005. Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans. J Virol 79:5833-5838. https://doi.org/10.1128/JVI.79.9.5833-5838.2005
29. Sheahan T, Whitmore A, Long K, Ferris M, Rockx B, Funkhouser W, Donaldson E, Gralinski L, Collier M, Heise M, Davis N, Johnston R, Baric RS. 2011. Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus. J Virol 85:217-230. https://doi.org/10.1128/JVI.01805-10
30. Roberts A, Deming D, Paddock CD, Cheng A, Yount B, Vogel L, Herman BD, Sheahan T, Heise M, Genrich GL, Zaki SR, Baric R, Subbarao K. 2007. A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog 3:e5. https://doi.org/10.1371/journal.ppat.0030005
31. Modjarrad K. 2016. MERS-CoV vaccine candidates in development: the current landscape. Vaccine 34:2982-2987. https://doi.org/10.1016/j.vaccine.2016.03.104
32. Scobey T, Yount BL, Sims AC, Donaldson EF, Agnihothram SS, Menachery VD, Graham RL, Swanstrom J, Bove PF, Kim JD, Grego S, Randell SH, Baric RS. 2013. Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus. Proc Natl Acad Sci U S A 110:16157-16162. https://doi.org/10.1073/pnas.1311542110
33. Cockrell AYB, Scobey T, Jensen K, Douglas M, Beall A, Tang X-C, Marasco WA, Heise MT, Baric RS. 2016. A mouse model for MERS coronavirus induced acute respiratory distress syndrome. Nat Microbiol 2:16226. https://doi.org/10.1038/nmicrobiol.2016.226
34. Yount B, Curtis KM, Fritz EA, Hensley LE, Jahrling PB, Prentice E, Denison MR, Geisbert TW, Baric RS. 2003. Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A 100:12995-13000. https://doi.org/10.1073/pnas.1735582100
35. Eckerle LD, Becker MM, Halpin RA, Li K, Venter E, Lu X, Scherbakova S, Graham RL, Baric RS, Stockwell TB, Spiro DJ, Denison MR. 2010. Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing. PLoS Pathog 6:e1000896. https://doi.org/10.1371/journal.ppat.1000896
36. Gralinski LE, Bankhead A, III, Jeng S, Menachery VD, Proll S, Belisle SE, Matzke M, Webb-Robertson BJ, Luna ML, Shukla AK, Ferris MT, Bolles M, Chang J, Aicher L, Waters KM, Smith RD, Metz TO, Law GL, Katze MG, McWeeney S, Baric RS. 2013. Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury. mBio 4:e00271-13. https://doi.org/10.1128/mBio.00271-13
37. Hosack DA, Dennis G, Jr, Sherman BT, Lane HC, Lempicki RA. 2003. Identifying biological themes within lists of genes with EASE. Genome Biol 4:R70. https://doi.org/10.1186/gb-2003-4-10-r70
38. Menachery VD, Yount BL, Jr, Sims AC, Debbink K, Agnihothram SS, Gralinski LE, Graham RL, Scobey T, Plante JA, Royal SR, Swanstrom J, Sheahan TP, Pickles RJ, Corti D, Randell SH, Lanzavecchia A, Marasco WA, Baric RS. 2016. SARS-like WIV1-CoV poised for human emergence. Proc Natl Acad Sci U S A 113:3048-3053. https://doi.org/10.1073/pnas.1517719113
39. Sims AC, Tilton SC, Menachery VD, Gralinski LE, Schafer A, Matzke MM, Webb-Robertson BJ, Chang J, Luna ML, Long CE, Shukla AK, Bankhead AR, III, Burkett SE, Zornetzer G, Tseng CT, Metz TO, Pickles R, McWeeney S, Smith RD, Katze MG, Waters KM, Baric RS. 2013. Release of severe acute respiratory syndrome coronavirus nuclear import block enhances host transcription in human lung cells. J Virol 87:3885-3902. https://doi.org/10.1128/JVI.02520-12